PRLD
insider transactionsPrelude Therapeutics Inc — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+3.5M
3.5M buy · 24.8K sell
Net value · 365d
-$463.3K
$12.5M in · $13.0M out
Sentiment · 365d
Net buying
49% buying · 51% selling
Open-market trades · 365d
33
3.5M buy · 24.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
15.6K sh
Own New
-
Grant·A
Director
$0
38.0K sh
Own New
-
Grant·A
Director
$0
38.0K sh
Own New
-
Grant·A
Director, 10% Owner
$0
38.0K sh
Own New
-
Grant·A
Director
$0
38.0K sh
Own New
-
Grant·A
Chief Medical Officer
$2.1M
450.0K sh · $4.70
Own New
-
Buy·P
Director, 10% Owner
$5.0M
1.1M sh · $4.44
Own New
-
Buy·P
Director, 10% Owner
$7.5M
1.7M sh · $4.44
Own +17%
-
Buy·P
Director
—
384.7K sh
Own New
-
Buy·P
Director
—
336.6K sh
Own New
-
Grant·A
Krishna Vaddi KEY
CEO
$0
837.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
230.0K sh
Own New
-
Grant·A
Bryant David Lim KEY
CLO, CFO, Corp Sec.
$0
275.0K sh
Own New
-
Grant·A
Chief Chemistry Officer
$0
230.0K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
280 sh
Own New
-
Sell·S
Director · 10b5-1
$154.3K
280 sh · $551.24
Own -0%
-
Exercise·M
Director · 10b5-1
$4.4K
280 sh · $15.80
Own +0%
-
Exercise·M
Director · 10b5-1
$0
24.5K sh
Own New
-
Sell·S
Director · 10b5-1
$21.8K
40 sh · $545.79
Own -0%
-
Sell·S
Director · 10b5-1
$324.2K
600 sh · $540.36
Own -0%
-
Sell·S
Director · 10b5-1
$258.8K
480 sh · $539.23
Own -0%
-
Sell·S
Director · 10b5-1
$43.0K
80 sh · $537.85
Own -0%
-
Sell·S
Director · 10b5-1
$261.5K
487 sh · $536.88
Own -0%
-
Sell·S
Director · 10b5-1
$253.5K
473 sh · $536.02
Own -0%
-
Sell·S
Director · 10b5-1
$79.2K
148 sh · $535.29
Own -0%
-
Sell·S
Director · 10b5-1
$177.3K
332 sh · $534.16
Own -0%
-
Sell·S
Director · 10b5-1
$42.6K
80 sh · $532.50
Own -0%
-
Sell·S
Director · 10b5-1
$148.6K
280 sh · $530.69
Own -0%
-
Sell·S
Director · 10b5-1
$87.9K
166 sh · $529.76
Own -0%
-
Sell·S
Director · 10b5-1
$365.7K
691 sh · $529.17
Own -0%
-
Sell·S
Director · 10b5-1
$303.7K
575 sh · $528.18
Own -0%
-
Sell·S
Director · 10b5-1
$822.1K
1.6K sh · $526.97
Own -1%
-
Sell·S
Director · 10b5-1
$560.7K
1.1K sh · $526.00
Own -1%
-
Sell·S
Director · 10b5-1
$1.3M
2.4K sh · $525.05
Own -1%
-
Sell·S
Director · 10b5-1
$628.4K
1.2K sh · $524.10
Own -1%
-
Sell·S
Director · 10b5-1
$507.3K
970 sh · $523.00
Own -0%
-
Sell·S
Director · 10b5-1
$438.5K
840 sh · $521.98
Own -0%
-
Sell·S
Director · 10b5-1
$354.8K
681 sh · $521.03
Own -0%
-
Sell·S
Director · 10b5-1
$439.8K
846 sh · $519.88
Own -0%
-
Sell·S
Director · 10b5-1
$707.0K
1.4K sh · $518.68
Own -1%
-
Sell·S
Director · 10b5-1
$1.3M
2.5K sh · $517.86
Own -1%
-
Sell·S
Director · 10b5-1
$395.9K
766 sh · $516.84
Own -0%
-
Sell·S
Director · 10b5-1
$1.0M
2.0K sh · $515.81
Own -1%
-
Sell·S
Director · 10b5-1
$692.2K
1.3K sh · $514.68
Own -1%
-
Sell·S
Director · 10b5-1
$561.3K
1.1K sh · $513.11
Own -1%
-
Sell·S
Director · 10b5-1
$757.7K
1.5K sh · $511.98
Own -1%
-
Exercise·M
Director · 10b5-1
$387.4K
24.5K sh · $15.80
Own +13%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | David P Bonita | Grant A | 15.6K | $0 |
| Jun 9, 2026 | Victor Sandor | Grant A | 38.0K | $0 |
| Jun 9, 2026 | Paul A Friedman | Grant A | 38.0K | $0 |
| Jun 9, 2026 | David P Bonita | Grant A | 38.0K | $0 |
| Jun 9, 2026 | Martin Babler | Grant A | 38.0K | $0 |
| May 1, 2026 | Charles Q Morris | Grant A | 450.0K | $2.1M |
| Apr 21, 2026 | David P Bonita | Buy P | 1.1M | $5.0M |
| Apr 21, 2026 | David P Bonita | Buy P | 1.7M | $7.5M |
| Apr 14, 2026 | David P Bonita | Buy P | 384.7K | — |
| Apr 14, 2026 | David P Bonita | Buy P | 336.6K | — |
| Feb 4, 2026 | Krishna Vaddi KEY | Grant A | 837.0K | $0 |
| Feb 4, 2026 | Peggy Scherle | Grant A | 230.0K | $0 |
| Feb 4, 2026 | Bryant David Lim KEY | Grant A | 275.0K | $0 |
| Feb 4, 2026 | Andrew Combs | Grant A | 230.0K | $0 |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Exercise M | 280 | $0 |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 280 | $154.3K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Exercise M | 280 | $4.4K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Exercise M | 24.5K | $0 |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 40 | $21.8K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 600 | $324.2K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 480 | $258.8K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 80 | $43.0K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 487 | $261.5K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 473 | $253.5K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 148 | $79.2K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 332 | $177.3K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 80 | $42.6K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 280 | $148.6K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 166 | $87.9K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 691 | $365.7K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 575 | $303.7K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 1.6K | $822.1K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 1.1K | $560.7K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 2.4K | $1.3M |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 1.2K | $628.4K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 970 | $507.3K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 840 | $438.5K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 681 | $354.8K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 846 | $439.8K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 1.4K | $707.0K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 2.5K | $1.3M |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 766 | $395.9K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 2.0K | $1.0M |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 1.3K | $692.2K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 1.1K | $561.3K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Sell S | 1.5K | $757.7K |
| Jan 9, 2026 | Paul A Friedman 10b5-1 | Exercise M | 24.5K | $387.4K |
About PRLD insider trading
This page tracks insider transactions for Prelude Therapeutics Inc (PRLD) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.